Cargando…
Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study
After the exclusion of iron deficiency and β-thalassemia, molecular research for α-thalassemia is recommended to investigate microcytic anemia. Aiming to suggest more efficiently the molecular analysis for individuals with a greater chance of having a symptomatic form of the disease, we have develop...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777031/ https://www.ncbi.nlm.nih.gov/pubmed/36553015 http://dx.doi.org/10.3390/diagnostics12123008 |
_version_ | 1784856004625694720 |
---|---|
author | Siqueira, Patricia F. R. Fleury, Marcos K. Pontes, Robéria M. Silva, Renata S. P. Costa, Elaine S. Land, Marcelo G. P. |
author_facet | Siqueira, Patricia F. R. Fleury, Marcos K. Pontes, Robéria M. Silva, Renata S. P. Costa, Elaine S. Land, Marcelo G. P. |
author_sort | Siqueira, Patricia F. R. |
collection | PubMed |
description | After the exclusion of iron deficiency and β-thalassemia, molecular research for α-thalassemia is recommended to investigate microcytic anemia. Aiming to suggest more efficiently the molecular analysis for individuals with a greater chance of having a symptomatic form of the disease, we have developed and validated a new decision tool to predict the presence of two or more deletions of α-thalassemia, increasing considerably the pre-test probability. The model was created using the variables: the percentage of HbA(2), serum ferritin and mean corpuscular volume standardized by age. The model was trained in 134 patients and validated in 160 randomly selected patients from the total sample. We used Youden’s index applied to the ROC curve methodology to establish the optimal odds ratio (OR) cut-off for the presence of two or more α-globin gene deletions. Using the OR cut-off of 0.4, the model’s negative predictive value (NPV) was 96.8%; the cut-off point accuracy was 85.4%; and the molecular analysis pre-test probability increased from 25.9% to 65.4% after the use of the proposed model. This tool aims to assist the physician in deciding when to perform molecular studies for the diagnosis of α-thalassemia. The model is useful in places with few financial health resources. |
format | Online Article Text |
id | pubmed-9777031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97770312022-12-23 Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study Siqueira, Patricia F. R. Fleury, Marcos K. Pontes, Robéria M. Silva, Renata S. P. Costa, Elaine S. Land, Marcelo G. P. Diagnostics (Basel) Article After the exclusion of iron deficiency and β-thalassemia, molecular research for α-thalassemia is recommended to investigate microcytic anemia. Aiming to suggest more efficiently the molecular analysis for individuals with a greater chance of having a symptomatic form of the disease, we have developed and validated a new decision tool to predict the presence of two or more deletions of α-thalassemia, increasing considerably the pre-test probability. The model was created using the variables: the percentage of HbA(2), serum ferritin and mean corpuscular volume standardized by age. The model was trained in 134 patients and validated in 160 randomly selected patients from the total sample. We used Youden’s index applied to the ROC curve methodology to establish the optimal odds ratio (OR) cut-off for the presence of two or more α-globin gene deletions. Using the OR cut-off of 0.4, the model’s negative predictive value (NPV) was 96.8%; the cut-off point accuracy was 85.4%; and the molecular analysis pre-test probability increased from 25.9% to 65.4% after the use of the proposed model. This tool aims to assist the physician in deciding when to perform molecular studies for the diagnosis of α-thalassemia. The model is useful in places with few financial health resources. MDPI 2022-12-01 /pmc/articles/PMC9777031/ /pubmed/36553015 http://dx.doi.org/10.3390/diagnostics12123008 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Siqueira, Patricia F. R. Fleury, Marcos K. Pontes, Robéria M. Silva, Renata S. P. Costa, Elaine S. Land, Marcelo G. P. Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study |
title | Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study |
title_full | Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study |
title_fullStr | Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study |
title_full_unstemmed | Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study |
title_short | Novel Decision Tool for More Severe α-Thalassemia Genotypes Screening with Functional Loss of Two or More α-Globin Genes: A Diagnostic Test Study |
title_sort | novel decision tool for more severe α-thalassemia genotypes screening with functional loss of two or more α-globin genes: a diagnostic test study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777031/ https://www.ncbi.nlm.nih.gov/pubmed/36553015 http://dx.doi.org/10.3390/diagnostics12123008 |
work_keys_str_mv | AT siqueirapatriciafr noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy AT fleurymarcosk noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy AT pontesroberiam noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy AT silvarenatasp noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy AT costaelaines noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy AT landmarcelogp noveldecisiontoolformoresevereathalassemiagenotypesscreeningwithfunctionallossoftwoormoreaglobingenesadiagnosticteststudy |